Drugs / Eloralintide
Eloralintide
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07701083 | Jul → Oct 2026 expected | — | Eli Lilly and Company | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07665879 | Jun 2026 → Aug 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07426380 | Feb → Oct 2026 expected | chronic renal failure syndrome, end stage renal failure, impaired renal function disease | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07401862 | Feb 2026 → Mar 2027 expected | liver disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06916091 | Apr → Sep 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06916065 | Apr 2025 → Jan 2026 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06297616 | Apr 2024 → Nov 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06345066 | Apr 2024 → Sep 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05295940 | Mar 2022 → Jan 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07589608 | May 2026 → Sep 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07215559 | Oct 2025 → Mar 2027 expected | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT06603571 | Sep 2024 → Jul 2026 overdue | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06230523 | Feb 2024 → May 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT06143956 | Nov 2023 → Sep 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07392190 | Feb 2026 → Jun 2028 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07369011 | Feb 2026 → Mar 2028 expected | obesity disorder, obstructive sleep apnea syndrome | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07353931 | Feb 2026 → Mar 2028 expected | obesity disorder, osteoarthritis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07321886 | Feb 2026 → Mar 2028 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07282600 | Dec 2025 → Jan 2028 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eloralintide | “Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity.” PMID 41109426 ↗ Oct 2025 |
| Known as | AMY-1176 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068462 ↗ |
| Known as | Eloralintida | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068462 ↗ |
| Known as | LY3841136 | “A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity” NCT06916065 ↗ |
| Action | Activate | “Eloralintide preferentially activated human AMY1R” PMID 41109426 ↗ Oct 2025 |
| Modality | Peptide | “Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity.” PMID 41109426 ↗ Oct 2025 |
| Modality | Protein / enzyme biologic | — CHEMBL6068462 ↗ |
| Route | Subcutaneous | “Single ascending doses of LY3841136 administered subcutaneously (SC).” NCT05295940 ↗ |